drugset / Trial / NCT00301223

A Study to Assess the Efficacy, Safety and Tolerability of Pregabalin in Patients With Symptoms of Neuropathic Pain

NCT00301223

Phase 3 Completed 309 enrolled Viatris Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of this study is to evaluate the efficacy, safety and tolerability for pregabalin using a flexible, optimized dose schedule compared to placebo in relieving the symptoms of neuropathic pain.

Timeline

Start
2006-02
Primary completion
Completion
2007-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Pregabalin Small molecule 150 mg
Subject Pregabalin Small molecule 600 mg

Indications